Skip to content
SuperAnalyst Interactive Dashboard

Explore a Real SuperAnalyst Dashboard On Big Pharma Q3 2026 Earnings

Earnings season buries teams in releases, transcripts, and decks, and the headline numbers rarely tell you what actually shifted. Instead of sorting through it all yourself, see it in one place. We gave SuperAnalyst the assignment, and it covered eight big pharma companies, separated one-time changes from lasting trends, and connected each company’s quarter to its competitors’.

Trusted by 8,000+ of the world’s largest enterprises

Pfizermicrosoft logoJ.P. Morgan logoPG&EBlue MCKESSON logo with an orange square below the 'C'.
SuperAnalyst text with a diamond and lightning bolt logo on a dark blue background with abstract shapes.

What the SuperAnalyst big pharma earnings dashboard shows

One dashboard that takes you from the big picture to each company’s results, with four views and eight company pages.

  1. Overview. The quarter on one screen: who grew fastest, who stalled, and how full-year guidance moved, with a five-quarter revenue view across all eight companies.
  2. Earnings & Guidance. Headline results and FY26 guidance side by side, plus a clear read on how acquired IPR&D charges distort EPS, so an EPS cut isn’t mistaken for weak performance.
  3. Growth Drivers. Winners and decliners by therapy class, from obesity and immunology to oncology and vaccines, showing where volume, pricing, new launches, and patent expiries are moving the numbers.
  4. Competitive Read-Through. What each company’s quarter means for everyone else, across obesity, immunology, and oncology, with the signals worth watching next.
  5. Company tabs. A focused view for each of the eight reporters: Lilly, Novo Nordisk, Merck, Pfizer, AstraZeneca, Johnson & Johnson, AbbVie, and Bristol Myers Squibb.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.